Coherus Oncology
CHRS
94 hedge funds and large institutions have $436M invested in Coherus Oncology in 2017 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 27 reducing their positions, and 14 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 27
1% more funds holding
Funds holding: 93 → 94 (+1)
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
5.97% less ownership
Funds ownership: 91.37% → 85.4% (-6%)
31% less capital invested
Capital invested by funds: $627M → $436M (-$191M)
41% less call options, than puts
Call options by funds: $590K | Put options by funds: $1.01M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$16.9M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$10.5M |
| 3 |
Millennium Management
New York
|
+$6.67M |
| 4 |
O
OrbiMed
New York
|
+$4.19M |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$4.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.9M |
| 2 |
CC
Carlson Capital
Dallas,
Texas
|
-$9.72M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.29M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$3.13M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$1.94M |
CHRS Hedge Fund Activity: Q4 2017 in Review
94 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q4 2017, worth a combined $436M — down 31% from $627M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new CHRS positions and 14 closed out — a net gain of 1 holder — while 36 added to existing stakes and 27 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $16.9M. The largest seller was Fidelity Investments, cutting an estimated $10.9M.
- 94 institutional investors held Coherus Oncology (CHRS) as of Q4 2017, up from 93 in Q3 2017.
- Funds reported $436M of Coherus Oncology stock for Q4 2017, down 31% quarter-over-quarter.
- 15 funds opened new Coherus Oncology positions in Q4 2017 and 14 closed out, a net change of +1 holder.
- The largest Coherus Oncology buyer in Q4 2017 was Citadel Advisors, an estimated $16.9M added.
- The largest Coherus Oncology seller in Q4 2017 was Fidelity Investments, an estimated $10.9M sold.
Based on aggregated 13F filings for Q4 2017.